GlassScriptPhysician profile
Anthony A Chestang
NPI 1427119700
$4,796.68
in general payments reported to CMS, 2019-2025
32 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 88% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $90.95 · 2021: $17.68 · 2022: $155 · 2023: $950 · 2024: $1,029 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $893.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $651.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $471.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $368.97 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $322.86 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $303.54 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $238.86 | 2024-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $219.68 | 2019-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $191.22 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $162.88 | 2019-2020 | |
| Corcept Therapeutics | $138.23 | 2023-2025 | Korlym |
| Abbott Laboratories | $116.74 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $108.17 | 2019 | |
| Amarin Pharma, INC. | $68.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.21 | 2019-2023 | Jardiance, Synjardy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $63.77 | 2024 | |
| Allergan, INC. | $62.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $51.41 | 2019 | |
| Xeris Pharmaceuticals, INC. | $36.62 | 2024 | Gvoke Hypopen |
| Shield Therapeutics INC | $34.11 | 2023 | Accrufer |
| Sanofi-Aventis U.S. LLC | $33.60 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $30.36 | 2024 | Austedo Xr |
| Mylan Specialty L.P. | $20.45 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.38 | 2025 | Voquezna |
| Lundbeck LLC | $17.24 | 2025 | Rexulti |
| Exact Sciences Corporation | $16.22 | 2024 | Cologuard Collection Kit |
| Radius Health, INC. | $16.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.51 | 2023 | Xifaxan |
| Vertex Pharmaceuticals Incorporated | $14.98 | 2025 | |
| Genentech USA, INC. | $14.86 | 2019 | |
| Sumitomo Pharma America, INC. | $13.68 | 2025 | Gemtesa |
| Integra Lifesciences Corporation | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Chestang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.